What can I give to a patient with End-Stage Renal Disease (ESRD) on hemodialysis experiencing back spasms as an alternative to baclofen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternative Medications for Back Spasms in ESRD Patients on Hemodialysis

For patients with End-Stage Renal Disease (ESRD) on hemodialysis experiencing back spasms, gabapentin is the recommended alternative to baclofen, administered at a dose of 100-300 mg after each dialysis session (three times per week). 1

Why Baclofen Should Be Avoided

  • Baclofen is primarily excreted by the kidneys (69-85%) and can accumulate to toxic levels in patients with ESRD, even at low doses 2, 3
  • Baclofen toxicity in ESRD patients can cause severe neurotoxicity including altered consciousness, encephalopathy, seizures, and hemodynamic instability 4, 5
  • Even a single dose of baclofen (25mg) has been reported to cause toxicity in ESRD patients 3
  • Studies show that ESRD patients generally develop baclofen intoxication soon after initiation of therapy, regardless of dosage 6

Recommended Alternative: Gabapentin

Dosing in ESRD:

  • Start with 100-300 mg after each hemodialysis session (three times weekly) 1
  • The minimal effective dose of gabapentin is not established, but clinical trials have shown good response with 100 mg post-dialysis three times weekly 1
  • Gabapentin can be removed from plasma by hemodialysis, making it safer for ESRD patients when properly dosed 7

Evidence for Efficacy:

  • Double-blind, placebo-controlled trials have shown significant improvement in ESRD patients receiving gabapentin compared to placebo 1
  • The American Academy of Sleep Medicine suggests gabapentin use in ESRD patients (conditional recommendation) 1
  • Gabapentin has been shown to improve both pain symptoms and associated sleep disturbances in dialysis patients 1

Important Monitoring Considerations

  • Monitor for side effects, particularly drowsiness, which is the most commonly reported adverse effect 1
  • Administer gabapentin after hemodialysis sessions to avoid premature removal of the drug 1
  • Consider monitoring serum drug concentrations in ESRD patients to minimize dose-related toxicity while providing effective doses 1
  • Be aware that patients with ESRD may have additional clinical conditions that affect drug absorption or interactions 1

Alternative Options to Consider

  • Topical capsaicin cream may be considered as a non-systemic alternative for localized back spasms 1
  • Ketotifen (1 mg daily) has shown improvement in some ESRD patients and may be comparable to gabapentin in efficacy 1
  • For patients in palliative care situations, sedative antihistamines may be considered, though they should generally be avoided long-term due to potential cognitive effects 1

Medication Reconciliation Importance

  • Ensure proper medication reconciliation at each transition of care to prevent inappropriate dosing of medications in ESRD patients 1
  • Document the adjusted medication regimen clearly to prevent dosing errors when patients transition between care settings 1

Remember that medication management in ESRD requires special attention to dosing, timing relative to dialysis, and monitoring for adverse effects to ensure both efficacy and safety.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Baclofen Toxicity in Kidney Disease.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.